Tariffs Changed the MedTech Playbook

Good morning, ! Today we’re examining the emerging MedTech onshoring playbook, as tariff pressure pushes healthcare manufacturers to rethink global supply chains and expand domestic production. We also break down McKesson and CD&R’s $5.8 billion take-private of Option Care Health, which gives McKesson a 49% stake for roughly $1.4 billion and an option to acquire CD&R’s remaining 51% over time.

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

MICROSURVEY

Finally, a Monday that doesn’t feel like one.

Imagine a Saturday where you're not catching up on the CRM you didn't touch all week. 

HubSpot's new self-updating CRM doesn't wait for you to log back in. Friday's calls are already logged. The deal that needs a nudge Monday morning is already flagged. The automation you set up once keeps running without you thinking about it. None of it needed you over the weekend. 

Customers are already seeing it pay off: 45% more deals closed. Finally, you start Monday caught up, not behind.

Get a Demo

HEADLINE OF THE WEEK

U.S. Tariff Deal Pushes MedTech Onshore : Healthcare Supply Chains Enter the Reshoring Era

So What? Becton Dickinson’s $19 billion U.S. investment commitment in exchange for tariff relief—the first deal of its kind for a major medical-device company—creates a potential template for MedTech, raising the strategic value of domestic manufacturing capacity while increasing capital requirements and policy exposure for globally distributed healthcare supply chains.

I’d pick this over this week’s pharma pricing developments because the BD agreement potentially changes the industry-wide manufacturing calculus: $3 billion is earmarked for U.S. manufacturing expansion, domestic supply of essential consumables is targeted to reach roughly 80%, and analysts are already flagging the possibility of similar MedTech agreements. (More)

DEAL OF THE WEEK

McKesson’s $5.8B Bet on Moving Infusion Out of the Hospital

McKesson and CD&R are taking Option Care Health private in a $5.8 billion transaction, giving McKesson a 49% stake for roughly $1.4 billion and the right to acquire CD&R’s remaining 51% later. The $32.05 per share offer represents a 37.1% premium to Option Care’s prior close.

The strategic logic is bigger than distribution. Option Care is the largest independent U.S. infusion provider, treating more than 308,000 patients annually across 197+ locations. That gives McKesson direct exposure to the shift of complex drug administration from hospitals into lower cost home and ambulatory settings.

The structure is equally important. McKesson gains strategic access without immediately absorbing the entire asset, while preserving a pathway to full ownership if the model delivers.

Why it matters: specialty drugs are becoming more important to McKesson’s growth, with oncology and multispecialty revenue reaching $14.2 billion, up 33% year over year. Option Care adds the care delivery infrastructure around those therapies. If site of care continues shifting outward, controlling both specialty distribution and infusion capacity could become a meaningful competitive advantage. (More)

DEAL TRACKER

Shionogi → IntraBio | $2.0B upfront
Shionogi signed an agreement to acquire IntraBio, which adds the rare-disease drug AQNEURSA (levacetylleucine) to its portfolio. Closing is planned for Nov–Dec 2026. Read more

GE HealthCare → SOFIE Biosciences | $945M cash
GE HealthCare agreed to buy SOFIE from Trilantic North America, which gives it a U.S. "final mile" supply network for PET radiopharmaceuticals. Closing is expected in 1H 2027. Read more

TPG + Hong Leong → Columbia Asia | Undisclosed
TPG and Hong Leong Group signed an agreement to acquire Columbia Pacific's Columbia Asia hospital network in Southeast Asia. Closing is expected by year-end. Read more

Harbor Health → Village Medical Houston clinics (27) | Undisclosed
Harbor Health is buying 27 Village Medical clinics in Houston, which brings it to nearly 70 Texas clinics alongside its insurance plans. Closing is expected at year-end. Read more

REGIONAL FOCUS

India’s Pharma Export Engine Keeps Expanding

India is consolidating its position as a critical node in the global pharmaceutical supply chain. Pharmaceutical exports reached a record $30.47 billion in FY2024–25, up 9.4% year-on-year, while separate calendar-year data shows exports climbing further from $27.75 billion in 2024 to $30.45 billion in 2025.

The scale is increasingly matched by geographic reach. Indian pharmaceutical products were exported to 191 countries, with roughly half of exports destined for highly regulated markets including the US and Europe. India also remains the world’s third-largest pharmaceutical producer by volume, supported by more than 3,000 pharmaceutical companies and 10,500 manufacturing facilities.

For global healthcare companies, the implication is that India’s role is evolving beyond low-cost generics. Rising exports, expanding regulated-market penetration and new investment in biopharma manufacturing capacity are pushing the country deeper into global sourcing strategies. The opportunity is significant, but so is the strategic question: as pharma companies diversify supply chains, India is increasingly positioned to capture production that historically concentrated elsewhere. (More)

INTERESTING ARTICLES